Lunit and CellCarta Partner to Advance AI in Digital Pathology

Lunit, a leader in clinical AI-cancer diagnostics, and CellCarta, a global CRO laboratory, announced a strategic collaboration aimed at accelerating the use of artificial intelligence in digital pathology for companion diagnostic (CDx) development. The partnership will combine Lunit’s AI-based image analysis technology with CellCarta’s laboratory and biomarker services. The goal is to support pharmaceutical companies in developing companion diagnostics that help match patients with targeted therapies based on biomarker data. The collaboration aims to integrate Lunit SCOPE AI digital pathology products with CellCarta workflows to support biomarker strategy, image analysis and CDx readiness.

Digital pathology involves analyzing tissue samples using high-resolution imaging and computational tools. By applying AI models to these images, the companies aim to improve the identification of disease patterns and biomarkers relevant to treatment decisions. Companion diagnostics play a growing role in precision medicine, particularly in oncology, where therapies are increasingly tailored to specific patient characteristics. Under the collaboration, initial focus areas include de-risking, translational and clinical workflows, platform-agnostic deployment and a real-world global pilot.

Posted by MedCloudInsider Editors on 03/30/2026